Alzinova AB is a Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. The company's proprietary AβCC peptide™ technology provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the synapse-damaging oligomers. It is currently under validation as a diagnostic tool.
Alzinova’s vaccine ALZ-101, has successfully been evaluated in a novel species and via a novel… Read more »
Alzinova’s AβCC patent has now been validated in 24 European countries comprising a very large potential market… Read more »
As previously reported, the European patent organisation EPO informed Alzinova that it intends to grant… Read more »